Publications by authors named "C Andreadis"

Claim this Profile
F
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
Richard T Maziarz, Michael R Bishop, Constantine S Tam, Peter Borchmann, Nina Worel, Charalambos Andreadis

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.
Charalambos Andreadis, Olivia Bobek, Eric D Hsi, Timothy S Fenske, Patrick J Stiff

Leuk Lymphoma· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographic, behavioral, and ecological data from a long-term field study of wild baboons in Amboseli, Kenya.
Chelsea A Southworth, Jack C Winans, Jacob B Gordon, Niki H Learn, William A Wilber, Catherine Andreadis

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.
Tamer Othman, Mimi M Lo, Charalambos B Andreadis, Lloyd E Damon, Timothy T Ferng

Leuk Lymphoma· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma.
Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, Charles Gaulin, Evandro Bezerra, Charalambos B Andreadis

Am J Hematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis